Why is Jagsonpal Pharmaceuticals Ltd ?
1
With ROE of 17, it has a Very Expensive valuation with a 5.8 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -25.98%, its profits have risen by 60.3% ; the PEG ratio of the company is 0.6
2
Despite the size of the company, domestic mutual funds hold only 0% of the company
- Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
3
Underperformed the market in the last 1 year
- Even though the market (BSE500) has generated returns of 2.13% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -25.98% returns
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Jagsonpal Pharma for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Jagsonpal Pharma
-25.59%
-0.47
54.82%
Sensex
4.84%
0.41
11.83%
Quality key factors
Factor
Value
Sales Growth (5y)
12.12%
EBIT Growth (5y)
35.17%
EBIT to Interest (avg)
31.03
Debt to EBITDA (avg)
0.30
Net Debt to Equity (avg)
-0.59
Sales to Capital Employed (avg)
1.31
Tax Ratio
21.23%
Dividend Payout Ratio
58.85%
Pledged Shares
0
Institutional Holding
2.21%
ROCE (avg)
36.15%
ROE (avg)
16.16%
Valuation Key Factors 
Factor
Value
P/E Ratio
34
Industry P/E
34
Price to Book Value
5.78
EV to EBIT
28.64
EV to EBITDA
23.74
EV to Capital Employed
12.79
EV to Sales
4.64
PEG Ratio
0.58
Dividend Yield
1.14%
ROCE (Latest)
44.66%
ROE (Latest)
16.98%
Loading Valuation Snapshot...
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Technical Movement
9What is working for the Company
PBDIT(Q)
Highest at Rs 16.44 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 22.08%
PBT LESS OI(Q)
Highest at Rs 13.78 cr.
PAT(Q)
At Rs 12.57 cr has Grown at 20.3% (vs previous 4Q average
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Jagsonpal Pharma
Operating Profit (PBDIT) - Quarterly
Highest at Rs 16.44 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 22.08%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 13.78 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 13.78 cr has Grown at 23.5% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 11.16 CrMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 12.57 cr has Grown at 20.3% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 10.45 CrMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Here's what is not working for Jagsonpal Pharma
Non Operating Income - Quarterly
Highest at Rs 3.03 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income






